• Lineage Cell Therapeutics posted GAAP net income of $1.5 million, swinging from a net loss of $30.5 million a year earlier; basic EPS was $0.01.
• Revenue fell 61.34% to $1.1 million, due to lower Roche collaboration revenue recognition and lower VAC-related revenue; WDI collaboration revenue partly offset.
• Operating loss narrowed 54.9% to $8.9 million, on total operating expenses falling 55.69% to $10 million due to the prior-year $14.8 million VAC impairment.
• Cash, cash equivalents, and marketable securities totaled $50.8 million at June 30, expected to fund operations into Q3 2028.
• Genentech’s Phase 2a GAlette study for RG6501 remained active at 17 sites; COR1 advanced to in-vivo testing with initial preclinical data expected in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lineage Cell Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260806053201) on August 06, 2026, and is solely responsible for the information contained therein.